リウマチ性関節炎患者のイグルラチモド治療中の腎臓機能障害のリスク: サラゾスルファピリジン併用の役割

Shunichiro Hanai¹, Yoshiaki Kobayashi¹, Moe Watanabe¹

¹Department of Rheumatology, University of Yamanashi Hospital, Japan.

Internal medicine (Tokyo, Japan)

|September 3, 2025

まとめ

イグルチモド (IGU) とサラゾスルファピリジン (SASP) の併用は,リウマチ性関節炎患者の腎臓機能を損なう可能性があります. SASPは,IGUと併用すると,腎臓機能低下の重大な危険因子として特定されています.

科学分野:

リウマトロジ
腎臓科
薬理学について

背景:

イグラチモド (IGU) は,東アジアで使用される疾患変異性抗レウマチック薬である.
IGUに関連した腎不全は認識されていないかもしれません.
IGUに関連した腎臓機能障害の割合,重症度,および危険因子は不明である.

研究の目的:

リウマチ性関節炎 (RA) の患者の腎機能に対するIGUの影響を評価する.
IGU 治療中に腎臓機能障害に関連する危険因子を特定する.

主な方法:

IGUで治療されたRA患者における腎機能の遡及評価 (eGFR).
3ヶ月後のEGFR変化 (ΔeGFR) の計算;腎機能障害はΔeGFR ≥15%として定義される.
バイノミアルロジスティック回帰と傾向スコアをマッチングしてリスク要因を特定する.

主要な成果:

108人の患者の30%に ΔeGFR ≥15%が示された.
サラゾスルファピリジン (SASP) の併用は腎臓機能障害の患者でより頻繁であった.
SASPは,eGFRを減少させる唯一の重要な独立リスク因子として浮上した.

結論:

IGUとSASPを組み合わせると,IGUだけでより大きなeGFRの減少につながります.
SASPは,IGUを受けたRA患者の腎臓機能障害の独立リスク因子である.
これは,IGUとSASPを併用する際の腎機能のモニタリングの必要性を強調しています.

キーワード:

5アミノサリシル酸慢性腎臓疾患サイクロオキシゲネーゼ非ステロイド抗炎症薬サルファサラジン

さらに関連する動画

04:37

Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis

Published on: April 25, 2025

772

11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

4.7K

関連する概念動画

01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...

01:11

Renal Failure: Dose Adjustments

152

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...

152

01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

264

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

264

01:22

Acute Kidney Injury I: Introduction

Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...

01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...

01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...

関連する実験動画